549 results on '"Drayson, Mark T"'
Search Results
2. Physical activity and sleep relate to antibody maintenance following naturalistic infection and/or vaccination in older adults
3. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
4. Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination
5. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
6. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
7. Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
8. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
9. Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies
10. Brief cycling intervals incrementally increase the number of hematopoietic stem and progenitor cells in human peripheral blood.
11. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
12. Salivary free light chains as a new biomarker to measure psychological stress: the impact of a university exam period on salivary immunoglobulins, cortisol, DHEA and symptoms of infection
13. Free light chains as an emerging biomarker in saliva: Biological variability and comparisons with salivary IgA and steroid hormones
14. Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples
15. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
16. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
17. Selective effects of acute low-grade inflammation on human visual attention
18. Loneliness in healthy young adults predicts inflammatory responsiveness to a mild immune challenge in vivo
19. Immunoglobulin free light chains: an inflammatory biomarker of diabetes
20. The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
21. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
22. Low-grade inflammation decreases emotion recognition – Evidence from the vaccination model of inflammation
23. Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation
24. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
25. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
26. Feasibility Of A Progressive Walking-based Exercise Programme In Clonal Plasma Cell Disorders: 4004 Board #321 May 30 9:00 AM - 10:30 AM
27. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
28. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
29. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial
30. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
31. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
32. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection.
33. Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3-inflammasome activation.
34. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.
35. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
36. Raised levels of immunoglobulin G, A and M are associated with an increased risk of total and cause-specific mortality: the Vietnam Experience Study
37. Correction to: Immunoglobulin free light chains: an inflammatory biomarker of diabetes
38. Vaccine-induced inflammation attenuates the vascular responses to mental stress
39. Underlying inflammation has no impact on the oxidative stress response to acute mental stress
40. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
41. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
42. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden
43. A population‐based study of the impact of dialysis on mortality in multiple myeloma
44. Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival
45. Deep immune B and plasma cell repertoire in non-small cell lung cancer.
46. Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
47. Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies.
48. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial.
49. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
50. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.